{ "instance": { "cenb20210930_10q.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 361, "dts": { "calculationLink": { "local": [ "cenb-20210930_cal.xml" ] }, "definitionLink": { "local": [ "cenb-20210930_def.xml" ] }, "inline": { "local": [ "cenb20210930_10q.htm" ] }, "labelLink": { "local": [ "cenb-20210930_lab.xml" ] }, "presentationLink": { "local": [ "cenb-20210930_pre.xml" ] }, "schema": { "local": [ "cenb-20210930.xsd" ], "remote": [ "https://xbrl.sec.gov/country/2021/country-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 555, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 114, "http://www.cenbiotechinc.com/20210930": 22, "http://xbrl.sec.gov/dei/2021": 6, "total": 142 }, "keyCustom": 66, "keyStandard": 336, "memberCustom": 64, "memberStandard": 31, "nsprefix": "cenb", "nsuri": "http://www.cenbiotechinc.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Property, Plant and Improvements, Net", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net", "shortName": "Note 4 - Property, Plant and Improvements, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:AdvancesToRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "shortName": "Note 5 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:AdvancesToRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Intangible Assets", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "shortName": "Note 6 - Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Loans Payable", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "shortName": "Note 7 - Loans Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:LoansPayableToRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Loans Payable- Related Party", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "shortName": "Note 8 - Loans Payable- Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:LoansPayableToRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Convertible Notes", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "shortName": "Note 9 - Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Convertible Notes Payable - Related Parties", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "shortName": "Note 10 - Convertible Notes Payable - Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:LoanPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - CEBA Loan Payable", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "shortName": "Note 11 - CEBA Loan Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:LoanPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:GovernmentalAssistanceDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Governmental Assistance", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "shortName": "Note 12 - Governmental Assistance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:GovernmentalAssistanceDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Leases", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "shortName": "Note 13 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Income Taxes", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes", "shortName": "Note 14 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 15 - Shareholders' Deficit / Stock Activity", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity", "shortName": "Note 15 - Shareholders' Deficit / Stock Activity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 16 - Related Party Transactions", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "shortName": "Note 16 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 17 - Stock Based Compensation", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "shortName": "Note 17 - Stock Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 18 - Net Loss Per Share", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share", "shortName": "Note 18 - Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 19 - Contingency", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency", "shortName": "Note 19 - Contingency", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 20 - Fair Value Disclosures", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures", "shortName": "Note 20 - Fair Value Disclosures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 21 - Segment Information", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information", "shortName": "Note 21 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 22 - Subsequent Events", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "shortName": "Note 22 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 3 - Acquisition of Clear Com Media, Inc (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables", "shortName": "Note 3 - Acquisition of Clear Com Media, Inc (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables", "shortName": "Note 4 - Property, Plant and Improvements, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 6 - Intangible Assets (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables", "shortName": "Note 6 - Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 7 - Loans Payable (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables", "shortName": "Note 7 - Loans Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "cenb:LoansPayableToRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:ScheduleOfLoansPayableToRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 8 - Loans Payable- Related Party (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables", "shortName": "Note 8 - Loans Payable- Related Party (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "cenb:LoansPayableToRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:ScheduleOfLoansPayableToRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 9 - Convertible Notes (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables", "shortName": "Note 9 - Convertible Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:ScheduleOfConvertibleNotesPayableToRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 10 - Convertible Notes Payable - Related Parties (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables", "shortName": "Note 10 - Convertible Notes Payable - Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cenb:ScheduleOfConvertibleNotesPayableToRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 13 - Leases (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables", "shortName": "Note 13 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 14 - Income Taxes (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables", "shortName": "Note 14 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 17 - Stock Based Compensation (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables", "shortName": "Note 17 - Stock Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "shortName": "Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:LaborAndRelatedExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 18 - Net Loss Per Share (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables", "shortName": "Note 18 - Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 20 - Fair Value Disclosures (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables", "shortName": "Note 20 - Fair Value Disclosures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 21 - Segment Information (Tables)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables", "shortName": "Note 21 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cenb:RecentDevelopmentsPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-09_2021-07-09_TitleOfIndividualAxis-ChiefTechnologyOfficerMember", "decimals": "INF", "lang": null, "name": "cenb:AnnualSalary", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 2 - Going Concern Uncertainty / Management Plans (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual", "shortName": "Note 2 - Going Concern Uncertainty / Management Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 3 - Acquisition of Clear Com Media, Inc (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "shortName": "Note 3 - Acquisition of Clear Com Media, Inc (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-09_2021-07-09_BusinessAcquisitionAxis-ClearComMediaIncMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 3 - Acquisition of Clear Com Media, Inc - Estimate of Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "shortName": "Note 3 - Acquisition of Clear Com Media, Inc - Estimate of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-07-09_BusinessAcquisitionAxis-ClearComMediaIncMember", "decimals": "INF", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_BusinessAcquisitionAxis-ClearComMediaIncMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 3 - Acquisition of Clear Com Media, Inc - Proforma Results of Operations (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "shortName": "Note 3 - Acquisition of Clear Com Media, Inc - Proforma Results of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_BusinessAcquisitionAxis-ClearComMediaIncMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual", "shortName": "Note 4 - Property, Plant and Improvements, Net (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details", "shortName": "Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "shortName": "Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesReceivableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "shortName": "Note 5 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cenb:AdvancesToRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-05-06_LegalEntityAxis-EmergenceGlobalMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2016-09-12_2016-09-12", "decimals": "INF", "first": true, "lang": null, "name": "cenb:DevelopmentOfAcquiredTechnologyAnnualCompensationForSpecialist", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 6 - Intangible Assets (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "shortName": "Note 6 - Intangible Assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2016-09-12_2016-09-12", "decimals": "INF", "first": true, "lang": null, "name": "cenb:DevelopmentOfAcquiredTechnologyAnnualCompensationForSpecialist", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 6 - Intangible Assets - Intangible Assets (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details", "shortName": "Note 6 - Intangible Assets - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 7 - Loans Payable (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "shortName": "Note 7 - Loans Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_ShortTermDebtTypeAxis-ShorttermLoanPayableToPrivateInvestorsMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "shortName": "Note 7 - Loans Payable - Loans Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "shortName": "Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 8 - Loans Payable- Related Party (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "shortName": "Note 8 - Loans Payable- Related Party (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cenb:LoansPayableToRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_CounterpartyNameAxis-RelatedPartiesLendersMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cenb:ScheduleOfLoansPayableToRelatedPartyTableTextBlock", "cenb:LoansPayableToRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_LongtermDebtTypeAxis-LoansPayableToRelatedPartyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "shortName": "Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cenb:ScheduleOfLoansPayableToRelatedPartyTableTextBlock", "cenb:LoansPayableToRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_LongtermDebtTypeAxis-LoansPayableToRelatedPartyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_RelatedPartyTransactionsByRelatedPartyAxis-JosephByrneMember", "decimals": "2", "first": true, "lang": null, "name": "cenb:PercentageOfRelatedPartysEquityInterestOwned", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "shortName": "Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 9 - Convertible Notes (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual", "shortName": "Note 9 - Convertible Notes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesIntoCommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "shortName": "Note 9 - Convertible Notes - Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "shortName": "Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 10 - Convertible Notes Payable - Related Parties (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "shortName": "Note 10 - Convertible Notes Payable - Related Parties (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2020-12-31_LongtermDebtTypeAxis-ConvertibleDebtPayableToRelatedPartyMember", "decimals": "INF", "lang": null, "name": "cenb:InterestPayableRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cenb:ScheduleOfConvertibleNotesPayableToRelatedPartyTableTextBlock", "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_LongtermDebtTypeAxis-ConvertibleDebtPayableToRelatedPartyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "shortName": "Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cenb:ScheduleOfConvertibleNotesPayableToRelatedPartyTableTextBlock", "cenb:LongTermConvertibleNotesRelatedPartyTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_LongtermDebtTypeAxis-ConvertibleDebtPayableToRelatedPartyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "shortName": "Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 11 - CEBA Loan Payable (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "shortName": "Note 11 - CEBA Loan Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cenb:LoanPayableDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_DebtInstrumentAxis-CanadaEmergencyBusinessAccountLoanPayableMember_LineOfCreditFacilityAxis-RoyalBankOfCanadaMember_LongtermDebtTypeAxis-UnsecuredDebtMember", "decimals": "INF", "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "cenb:GovernmentalAssistanceDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_LegalEntityAxis-ClearComMediaIncMember", "decimals": "INF", "first": true, "lang": null, "name": "cenb:ProceedsFromGovernmentalAssistance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 12 - Governmental Assistance (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual", "shortName": "Note 12 - Governmental Assistance (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cenb:GovernmentalAssistanceDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_LegalEntityAxis-ClearComMediaIncMember", "decimals": "INF", "first": true, "lang": null, "name": "cenb:ProceedsFromGovernmentalAssistance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 13 - Leases (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "shortName": "Note 13 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2020-08-01_2020-08-01_LeaseContractualTermAxis-LeasesOfficeSpaceFromRdLabsCanadaIncMember", "decimals": "INF", "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 13 - Leases - Future Minimum Operating Lease Payments (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details", "shortName": "Note 13 - Leases - Future Minimum Operating Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 14 - Income Taxes (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual", "shortName": "Note 14 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "shortName": "Note 1 - Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "3", "first": true, "lang": null, "name": "cenb:EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 14 - Income Taxes - Reconciliation of Effective Tax Rate (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details", "shortName": "Note 14 - Income Taxes - Reconciliation of Effective Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "3", "first": true, "lang": null, "name": "cenb:EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 14 - Income Taxes - Deferred Tax Assets (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details", "shortName": "Note 14 - Income Taxes - Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 15 - Shareholders' Deficit / Stock Activity (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual", "shortName": "Note 15 - Shareholders' Deficit / Stock Activity (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesReceivableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 16 - Related Party Transactions (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "shortName": "Note 16 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2017-01-01_2017-01-31_LeaseContractualTermAxis-LeaseArrangement20NorthRearRoadMember", "decimals": "INF", "lang": null, "name": "cenb:OperatingLeaseMonthlyRent", "reportCount": 1, "unique": true, "unitRef": "CAD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 17 - Stock Based Compensation (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "shortName": "Note 17 - Stock Based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-13_2021-07-13", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note 17 - Stock Based Compensation - Restricted Stock Award Activity (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details", "shortName": "Note 17 - Stock Based Compensation - Restricted Stock Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30_AwardTypeAxis-RestrictedStockMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note 18 - Net Loss Per Share - Antidilutive Securities (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details", "shortName": "Note 18 - Net Loss Per Share - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note 20 - Fair Value Disclosures - Fair Value of Financial Instruments (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "shortName": "Note 20 - Fair Value Disclosures - Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note 21 - Segment Information (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-details-textual", "shortName": "Note 21 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note 21 - Segment Information - Segment Information (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details", "shortName": "Note 21 - Segment Information - Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_StatementBusinessSegmentsAxis-GrowthMember", "decimals": "INF", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Going Concern Uncertainty / Management Plans", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans", "shortName": "Note 2 - Going Concern Uncertainty / Management Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Note 21 - Segment Information - Segment Assets to Total Assets (Details)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "shortName": "Note 21 - Segment Information - Segment Assets to Total Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "i_2021-09-30_StatementBusinessSegmentsAxis-GrowthMember", "decimals": "INF", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Note 22 - Subsequent Events (Details Textual)", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "shortName": "Note 22 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-10-01_2021-11-19_LongtermDebtTypeAxis-ConvertibleDebtMember_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Acquisition of Clear Com Media, Inc", "role": "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "shortName": "Note 3 - Acquisition of Clear Com Media, Inc", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cenb20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 105, "tag": { "cenb_AcquisitionOfIntangibleAssetsLiabilityIncurredNoncurrent": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of liability incurred due to the acquisition of certain intangible assets. Classified as noncurrent.", "label": "Patent acquisition liability" } } }, "localname": "AcquisitionOfIntangibleAssetsLiabilityIncurredNoncurrent", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "cenb_AdvancesToRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for advances to related party.", "label": "Advances to Related Party [Text Block]" } } }, "localname": "AdvancesToRelatedPartyTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-" ], "xbrltype": "textBlockItemType" }, "cenb_AdvancesToSubsidiaryFairValuedisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of advances to subsidiary.", "label": "cenb_AdvancesToSubsidiaryFairValuedisclosure", "verboseLabel": "Advances to Subsidiary" } } }, "localname": "AdvancesToSubsidiaryFairValuedisclosure", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "cenb_AnnualSalary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of salary owed per year as per the employment contract.", "label": "cenb_AnnualSalary", "terseLabel": "Annual Salary" } } }, "localname": "AnnualSalary", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_BahigeChaabanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Bahige Chaaban.", "label": "Bahige Chaaban [Member]" } } }, "localname": "BahigeChaabanMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_BillChaabanPresidentOfCenBiotechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Bill Chaaban, a president of Cen Biotech.", "label": "Bill Chaaban, President of Cen Biotech [Member]" } } }, "localname": "BillChaabanPresidentOfCenBiotechMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_BoardMembersAndOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Board Member and officers of the company.", "label": "Board Members and Officers [Member]" } } }, "localname": "BoardMembersAndOfficersMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_BrianPayneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Brian Payne.", "label": "Brian Payne [Member]" } } }, "localname": "BrianPayneMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_BrotherOfDirectorAmeenFerrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the brother of director Ameen Ferris.", "label": "Brother of Director Ameen Ferris [Member]" } } }, "localname": "BrotherOfDirectorAmeenFerrisMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The pro forma earnings per share basic and diluted for the period as if the business combination or combinations had been completed at the beginning of a period", "label": "cenb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted", "terseLabel": "Basic and Diluted (in dollars per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "perShareItemType" }, "cenb_BusinessAcquisitionProFormaNonoperatingIncomeExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma nonoperating income (expense) for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "cenb_BusinessAcquisitionProFormaNonoperatingIncomeExpense", "terseLabel": "Other (expense) income" } } }, "localname": "BusinessAcquisitionProFormaNonoperatingIncomeExpense", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "cenb_BusinessAcquisitionProFormaOperatingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The pro forma operating expense for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "cenb_BusinessAcquisitionProFormaOperatingExpense", "terseLabel": "Operating expenses" } } }, "localname": "BusinessAcquisitionProFormaOperatingExpense", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "cenb_BusinessAcquisitionProFormaOperatingIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma operating income (loss) for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "cenb_BusinessAcquisitionProFormaOperatingIncomeLoss", "terseLabel": "Loss from operations" } } }, "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "cenb_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The pro forma weighted average number of shares outstanding for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "cenb_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "terseLabel": "Basic and Diluted (in shares)" } } }, "localname": "BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "sharesItemType" }, "cenb_CENBiotechUkraineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the entity CEN Biotech, Ukraine.", "label": "CEN Biotech Ukraine [Member]" } } }, "localname": "CENBiotechUkraineMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "domainItemType" }, "cenb_CONFIENSASMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to CONFIEN SAS.", "label": "CONFIEN SAS [Member]" } } }, "localname": "CONFIENSASMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_CanadaEmergencyBusinessAccountLoanPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Canada Emergency Business Account (\u201cCEBA\u201d) loan payable.", "label": "Canada Emergency Business Account Loan Payable [Member]" } } }, "localname": "CanadaEmergencyBusinessAccountLoanPayableMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual" ], "xbrltype": "domainItemType" }, "cenb_CebaLoanPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information on loan payable to CEBA.", "label": "CEBA, Loan Payable [Member]" } } }, "localname": "CebaLoanPayableMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "cenb_ChiefTechnologyOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the chief technology officer.", "label": "Chief Technology Officer [Member]" } } }, "localname": "ChiefTechnologyOfficerMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ClearComMediaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Clear Com Media, Inc.", "label": "Clear Com Media, Inc [Member]" } } }, "localname": "ClearComMediaIncMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ConsultingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to consulting fees.", "label": "Consulting Fees [Member]" } } }, "localname": "ConsultingFeesMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ConsultingFeesRelatedParty": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consulting fees related to related parties.", "label": "Consulting fees \u2013 related parties" } } }, "localname": "ConsultingFeesRelatedParty", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_ConversionOfConvertibleNotesIntoCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the conversion of convertible notes into common stock.", "label": "Conversion of Convertible Notes into Common Stock [Member]" } } }, "localname": "ConversionOfConvertibleNotesIntoCommonStockMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ConversionOfRelatedPartyConvertibleNotesIntoCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the conversion of related party convertible notes into common stock.", "label": "Conversion of Related Party Convertible Notes into Common stock [Member]" } } }, "localname": "ConversionOfRelatedPartyConvertibleNotesIntoCommonStockMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleDebtPayableToNonrelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents convertible debt payable to non-related party.", "label": "Convertible Debt Payable to Non-related Party [Member]" } } }, "localname": "ConvertibleDebtPayableToNonrelatedPartyMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleDebtPayableToRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the convertible debt payable to related party.", "label": "Convertible Debt Payable to Related Party [Member]" } } }, "localname": "ConvertibleDebtPayableToRelatedPartyMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleDebtPayableToRelatedPartyReclassifiedToPrivateInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the convertible debt payable to related party reclassified to private investor.", "label": "Convertible Debt Payable to Related Party Reclassified to Private Investor [Member]" } } }, "localname": "ConvertibleDebtPayableToRelatedPartyReclassifiedToPrivateInvestorMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleDebtRelatedPartyFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of convertible debt payable to related party.", "label": "cenb_ConvertibleDebtRelatedPartyFairValueDisclosures", "verboseLabel": "Convertible notes payable \u2013 related parties" } } }, "localname": "ConvertibleDebtRelatedPartyFairValueDisclosures", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "cenb_ConvertibleNotes1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the first group of convertible notes.", "label": "Convertible Notes 1[Member]" } } }, "localname": "ConvertibleNotes1Member", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleNotes2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the second group of convertible notes.", "label": "Convertible Notes 2 [Member]" } } }, "localname": "ConvertibleNotes2Member", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleNotes3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the third group of convertible notes.", "label": "Convertible Notes 3 [Member]" } } }, "localname": "ConvertibleNotes3Member", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ConvertibleNotesPayableRelatedPartiesCurrent": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and holder. Related to debt issued by related parties to the company.", "label": "Convertible notes payable- related parties" } } }, "localname": "ConvertibleNotesPayableRelatedPartiesCurrent", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "cenb_CreativeEdgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former parent entity of the company.", "label": "Creative Edge [Member]" } } }, "localname": "CreativeEdgeMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_DebtConversionAccruedInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the accrued interest on debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "cenb_DebtConversionAccruedInterestAmount", "terseLabel": "Debt Conversion, Accrued Interest, Amount" } } }, "localname": "DebtConversionAccruedInterestAmount", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_DebtInstrumentShareInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual share interest, per 30-day period, for funds borrowed under the debt agreement.", "label": "Share Interest (in shares)" } } }, "localname": "DebtInstrumentShareInterest", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "sharesItemType" }, "cenb_DevelopmentOfAcquiredTechnologyAnnualCompensationForSpecialist": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the annual compensation for specialist in connection with the development of the acquired technology.", "label": "cenb_DevelopmentOfAcquiredTechnologyAnnualCompensationForSpecialist", "terseLabel": "Development of Acquired Technology, Annual Compensation for Specialist" } } }, "localname": "DevelopmentOfAcquiredTechnologyAnnualCompensationForSpecialist", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_DigitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents digital segment.", "label": "Digital [Member]" } } }, "localname": "DigitalMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "domainItemType" }, "cenb_DirectorAlexTarrabainMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Alex Tarrabain, a director of the company.", "label": "Director, Alex Tarrabain [Member]" } } }, "localname": "DirectorAlexTarrabainMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_DirectorAmeenFerrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Ameen Ferris, a director of the company.", "label": "Director, Ameen Ferris [Member]" } } }, "localname": "DirectorAmeenFerrisMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_DirectorDonaldStrilchuckMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Donald Strilchuck, a director of the company.", "label": "Director,Donald Strilchuck [Member]" } } }, "localname": "DirectorDonaldStrilchuckMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_DirectorHaroldAubreyDeLavenuMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Harold Aubrey de Lavenu, a director of CEN.", "label": "Director, Harold Aubrey de Lavenu [Member]" } } }, "localname": "DirectorHaroldAubreyDeLavenuMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_DirectorsAmeenFerrisAndHaroldAubreyDeLavenuMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Directors Ameen Ferris and Harold Aubrey De Lavenu.", "label": "Directors Ameen Ferris and Harold Aubrey De Lavenu [Member]" } } }, "localname": "DirectorsAmeenFerrisAndHaroldAubreyDeLavenuMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_DonaldStrilchuckMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Donald Strilchuck.", "label": "Donald Strilchuck [Member]" } } }, "localname": "DonaldStrilchuckMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRatePercent": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of Canadian statutory tax rate applicable to pretax income (loss).", "label": "Income tax benefit at Canadian statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRatePercent", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "percentItemType" }, "cenb_EmergenceGlobalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Emergence Global.", "label": "Emergence Global [Member]" } } }, "localname": "EmergenceGlobalMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "domainItemType" }, "cenb_EmploymentAgreementBaseAnnualSalary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The base annual salary pursuant to the employment agreement.", "label": "cenb_EmploymentAgreementBaseAnnualSalary", "terseLabel": "Employment Agreement, Base Annual Salary" } } }, "localname": "EmploymentAgreementBaseAnnualSalary", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_EmploymentAgreementCompensationSharesOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares would issue to the employee as compensation for service pursuant to the employment agreement.", "label": "cenb_EmploymentAgreementCompensationSharesOfRestrictedStock", "terseLabel": "Employment Agreement, Compensation, Shares of Restricted Stock (in shares)" } } }, "localname": "EmploymentAgreementCompensationSharesOfRestrictedStock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_EquipmentSoldToRelatedPartyInExchangeForNoteReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the transaction related to the equipment sold to a related party in exchange for a note receivable.", "label": "Equipment Sold to Related Party in Exchange for Note Receivable [Member]" } } }, "localname": "EquipmentSoldToRelatedPartyInExchangeForNoteReceivableMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_EquityCompensation2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the 2017 Equity Compensation Plan", "label": "2017 Equity Compensation Plan [Member]" } } }, "localname": "EquityCompensation2017PlanMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_FairValueAdjustmentOfAquiredLiability": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value adjustment of an acquired liability.", "label": "cenb_FairValueAdjustmentOfAquiredLiability", "negatedLabel": "Change in fair value of patent acquisition liability", "verboseLabel": "Change in fair value of patent acquisition liability" } } }, "localname": "FairValueAdjustmentOfAquiredLiability", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearEight": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in eighth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearEight", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Eight" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearEight", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearEleven": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in eleventh fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearEleven", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Eleven" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearEleven", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearNine": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in ninth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearNine", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Nine" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearNine", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearSeven": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in seventh fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearSeven", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearSeven", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearSix": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearSix", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Six" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearSix", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearTen": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "cenb_FinitelivedIntangibleAssetExpectedAmortizationYearTen", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Ten" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearTen", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_FormerCEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to former CEO.", "label": "Former CEO [Member]" } } }, "localname": "FormerCEOMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "domainItemType" }, "cenb_GainLossOnTerminationOfLeaseIncludingSharesIssued": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term, including shares issued.", "label": "cenb_GainLossOnTerminationOfLeaseIncludingSharesIssued", "negatedLabel": "Loss on lease termination" } } }, "localname": "GainLossOnTerminationOfLeaseIncludingSharesIssued", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_GovernmentalAssistanceDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for government assistance.", "label": "Governmental Assistance Disclosure [Text Block]" } } }, "localname": "GovernmentalAssistanceDisclosureTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-" ], "xbrltype": "textBlockItemType" }, "cenb_GovernmentalAssistanceIncome": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents governmental assistance income.", "label": "Governmental assistance income" } } }, "localname": "GovernmentalAssistanceIncome", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_GrowthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents growth segment.", "label": "Growth [Member]" } } }, "localname": "GrowthMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "domainItemType" }, "cenb_IncreaseDecreaseInAccruedInterestRelatedAndNonrelatedParties": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the increase (decrease) in accrued interest for related and non-related parties.", "label": "Accrued interest \u2013 related and non-related parties" } } }, "localname": "IncreaseDecreaseInAccruedInterestRelatedAndNonrelatedParties", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_IndividualLendersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the individual lenders.", "label": "Individual Lenders [Member]" } } }, "localname": "IndividualLendersMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual" ], "xbrltype": "domainItemType" }, "cenb_IntangiblesExcludingLightingPatentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information on intangibles, excluding lighting patent.", "label": "Intangibles, Excluding Lighting Patent [Member]" } } }, "localname": "IntangiblesExcludingLightingPatentMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "cenb_InterestPayableRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on related party debt.", "label": "cenb_InterestPayableRelatedParty", "terseLabel": "Interest Payable, Related Party" } } }, "localname": "InterestPayableRelatedParty", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_InterestPayableRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest payable to related party classified as current.", "label": "cenb_InterestPayableRelatedPartyCurrent", "terseLabel": "Accrued interest \u2013 related parties" } } }, "localname": "InterestPayableRelatedPartyCurrent", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "cenb_IssuanceOfStockRelatedToLeaseTerminationSettlement": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the issuance of stock related to lease termination settlement.", "label": "Shares issued related to lease termination settlement" } } }, "localname": "IssuanceOfStockRelatedToLeaseTerminationSettlement", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_JeffThomasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former director of Creative Edge Nutrition (company's former Parent entity).", "label": "Jeff Thomas [Member]" } } }, "localname": "JeffThomasMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_JosephByrneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Joseph Byrne, CEO of CEN.", "label": "Joseph Byrne [Member]" } } }, "localname": "JosephByrneMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_LeaseArrangement20NorthRearRoadMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lease related to 20 North Rear Road.", "label": "Lease Arrangement, 20 North Rear Road [Member]" } } }, "localname": "LeaseArrangement20NorthRearRoadMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_LeaseExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents amount of lease expense", "label": "Lease expense" } } }, "localname": "LeaseExpenseBenefit", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_LeasesOfficeSpaceFromRdLabsCanadaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lease arrangement with R&D Labs Canada, Inc for office space.", "label": "Leases Office Space from R&D Labs Canada, Inc [Member]" } } }, "localname": "LeasesOfficeSpaceFromRdLabsCanadaIncMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_LightingPatentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to lighting patent.", "label": "Lighting Patent [Member]" } } }, "localname": "LightingPatentMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "domainItemType" }, "cenb_LoanPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loan payable.", "label": "Loan Payable , Disclosure [Text Block]" } } }, "localname": "LoanPayableDisclosureTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-" ], "xbrltype": "textBlockItemType" }, "cenb_LoansPayableRelatedPartyFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of loans payable to related party.", "label": "cenb_LoansPayableRelatedPartyFairValueDisclosure", "verboseLabel": "Loans payable \u2013 related parties" } } }, "localname": "LoansPayableRelatedPartyFairValueDisclosure", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "cenb_LoansPayableToRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the loans payable to related party.", "label": "Loans Payable to Related Party [Member]" } } }, "localname": "LoansPayableToRelatedPartyMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_LoansPayableToRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loans payable to related party.", "label": "Loans Payable to Related Party [Text Block]" } } }, "localname": "LoansPayableToRelatedPartyTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party" ], "xbrltype": "textBlockItemType" }, "cenb_LongTermConvertibleNotesPayableToMultiplePrivateInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents long-term convertible notes payable to multiple private investors.", "label": "Long-term Convertible Notes Payable to Multiple Private Investors [Member]" } } }, "localname": "LongTermConvertibleNotesPayableToMultiplePrivateInvestorsMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_LongTermConvertibleNotesRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term convertible notes related party.", "label": "Long-term Convertible Notes Related Party [Text Block]" } } }, "localname": "LongTermConvertibleNotesRelatedPartyTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties" ], "xbrltype": "textBlockItemType" }, "cenb_MrChaabansSpouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Mr. Chaaban's Spouse.", "label": "Mr. Chaaban's Spouse [Member]" } } }, "localname": "MrChaabansSpouseMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_NoncashServicesExpense": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the noncash services expense made during the period.", "label": "Non-cash services expense" } } }, "localname": "NoncashServicesExpense", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_NotesReceivableConvertedInstrumentSharesReceivedAsPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents shares received as payment for notes receivable.", "label": "cenb_NotesReceivableConvertedInstrumentSharesReceivedAsPayment", "terseLabel": "Notes Receivable, Converted Instrument, Shares Received as Payment (in shares)" } } }, "localname": "NotesReceivableConvertedInstrumentSharesReceivedAsPayment", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_NotesReceivableOriginalAmountConvertedToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents original amount converted to common stock for note receivable.", "label": "cenb_NotesReceivableOriginalAmountConvertedToCommonStock", "terseLabel": "Notes Receivable, Original Amount Converted to Common Stock" } } }, "localname": "NotesReceivableOriginalAmountConvertedToCommonStock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_NotesReceivableRelatedPartyFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes receivable from related party.", "label": "cenb_NotesReceivableRelatedPartyFairValueDisclosure", "verboseLabel": "Note receivable \u2013 CEN Biotech Ukraine, LLC \u2013 related party" } } }, "localname": "NotesReceivableRelatedPartyFairValueDisclosure", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "cenb_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "cenb_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "cenb_NumberOfRestrictedSharesToSettleAccruedSalaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of restricted shares that settled the accrued salaries.", "label": "cenb_NumberOfRestrictedSharesToSettleAccruedSalaries", "terseLabel": "Number of Restricted Shares to settle Accrued Salaries (in shares)" } } }, "localname": "NumberOfRestrictedSharesToSettleAccruedSalaries", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents one customer.", "label": "One Customer [Member]" } } }, "localname": "OneCustomerMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "cenb_OperatingLeaseMonthlyRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the monthly rent required for operating lease.", "label": "cenb_OperatingLeaseMonthlyRent", "terseLabel": "Operating Lease, Monthly Rent" } } }, "localname": "OperatingLeaseMonthlyRent", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_OtherReceivablesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other, expected to be collected after one year or the normal operating cycle, if longer.", "label": "Other receivable" } } }, "localname": "OtherReceivablesNoncurrent", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "cenb_OwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage of the entity.", "label": "cenb_OwnershipPercentage", "terseLabel": "Ownership Percentage" } } }, "localname": "OwnershipPercentage", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "percentItemType" }, "cenb_PatentAcquisitionLiabilityFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of patent acquisition liability.", "label": "cenb_PatentAcquisitionLiabilityFairValue", "verboseLabel": "Patent acquisition liability" } } }, "localname": "PatentAcquisitionLiabilityFairValue", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "cenb_PercentageOfRelatedPartysEquityInterestOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of a related party's equity interest owned of the company.", "label": "Related Party Interest", "terseLabel": "Percentage of Related Party's Equity Interest Owned" } } }, "localname": "PercentageOfRelatedPartysEquityInterestOwned", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "percentItemType" }, "cenb_PercentageOfRelatedPartysEquityInterestOwnedByDirector": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of a related party's equity equity interest owned by a director of the company.", "label": "cenb_PercentageOfRelatedPartysEquityInterestOwnedByDirector", "terseLabel": "Percentage of Related Party's Equity Interest Owned by Director" } } }, "localname": "PercentageOfRelatedPartysEquityInterestOwnedByDirector", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "percentItemType" }, "cenb_ProceedsFromGovernmentalAssistance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents cash inflow from government assistance.", "label": "cenb_ProceedsFromGovernmentalAssistance", "terseLabel": "Proceeds from Governmental Assistance" } } }, "localname": "ProceedsFromGovernmentalAssistance", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_PurchasedEquipmentInExchangeForNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the transaction related to the purchase of equipment in exchange of note payable.", "label": "Purchased Equipment in Exchange for Note Payable [Member]" } } }, "localname": "PurchasedEquipmentInExchangeForNotePayableMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_RDLabsCanadaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents R&D Labs Canada, Inc, a related party of the company.", "label": "R&D Labs Canada, Inc [Member]" } } }, "localname": "RDLabsCanadaIncMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_RecentDevelopmentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recent developments.", "label": "Recent Developments, Policy [Policy Text Block]" } } }, "localname": "RecentDevelopmentsPolicyPolicyTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "cenb_RelatedPartiesLendersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to related-party lenders.", "label": "Related Parties Lenders [Member]" } } }, "localname": "RelatedPartiesLendersMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "domainItemType" }, "cenb_RestrictedSharesIssuedForSecurityConsultingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the restricted shares issued for security consulting services.", "label": "Restricted Shares Issued for Security Consulting Services [Member]" } } }, "localname": "RestrictedSharesIssuedForSecurityConsultingServicesMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_RichardBoswellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Richard Boswell.", "label": "Richard Boswell [Member]" } } }, "localname": "RichardBoswellMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_RoyalBankOfCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Royal Bank of Canada.", "label": "Royal Bank of Canada [Member]" } } }, "localname": "RoyalBankOfCanadaMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ScheduleOfConvertibleNotesPayableToRelatedPartyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible notes payable to related party.", "label": "Schedule of Convertible Notes Payable to Related Party [Table Text Block]" } } }, "localname": "ScheduleOfConvertibleNotesPayableToRelatedPartyTableTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables" ], "xbrltype": "textBlockItemType" }, "cenb_ScheduleOfLoansPayableToRelatedPartyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of loans payable to related party.", "label": "Schedule of Loans Payable to Related Party [Table Text Block]" } } }, "localname": "ScheduleOfLoansPayableToRelatedPartyTableTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables" ], "xbrltype": "textBlockItemType" }, "cenb_SecondShortTermLoanPayableToAnIndividualMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a second short-term loan payable to an individual.", "label": "Second Short-term Loan Payable to an Individual [Member]" } } }, "localname": "SecondShortTermLoanPayableToAnIndividualMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Senior Executive Vice President and Chief Financial Officer of the company.", "label": "Senior Executive Vice President and Chief Financial Officer [Member]" } } }, "localname": "SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_ShareExchangeAgreementSharesToAcquire": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares the company will acquire under a share exchange agreement.", "label": "cenb_ShareExchangeAgreementSharesToAcquire", "terseLabel": "Share Exchange Agreement, Shares to Acquire (in shares)" } } }, "localname": "ShareExchangeAgreementSharesToAcquire", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_ShareExchangeAgreementSharesToIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of company stock that will be issued under a share exchange agreement.", "label": "cenb_ShareExchangeAgreementSharesToIssue", "terseLabel": "Share Exchange Agreement, Shares to Issue (in shares)" } } }, "localname": "ShareExchangeAgreementSharesToIssue", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards at the grant date.", "label": "cenb_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "cenb_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_ShortTermLoanPayableToAnIndividualMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining the short-term loan payable to an individual.", "label": "Short-term Loan Payable to an Individual [Member]" } } }, "localname": "ShortTermLoanPayableToAnIndividualMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the short-term loan payable to Global Holdings International, LLC.", "label": "Short-term Loan Payable to Global Holdings International, LLC [Member]" } } }, "localname": "ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ShortTermMortgagePayableToARGPalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents shot-term mortgage payable to ARG & Pals, Inc.", "label": "Short-term Mortgage Payable to ARG & Pals, Inc. [Member]" } } }, "localname": "ShortTermMortgagePayableToARGPalsIncMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ShorttermLoanPayableToMultipleInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents short-term loan payable to multiple investors.", "label": "Short-term Loan Payable to Multiple Investors [Member]" } } }, "localname": "ShorttermLoanPayableToMultipleInvestorsMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_ShorttermLoanPayableToPrivateInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents short-term loan payable to private investors.", "label": "Short-term Loan Payable to Private Investors [Member]" } } }, "localname": "ShorttermLoanPayableToPrivateInvestorsMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_SpouseOfJosephByrneCEOOfCENBiotechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the spouse of Joseph Bryne, CEO of CEN Biotech.", "label": "Spouse of Joseph Byrne, CEO of CEN Biotech [Member]" } } }, "localname": "SpouseOfJosephByrneCEOOfCENBiotechMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "cenb_StockIssuedDuringPeriodSharesIssuedForSettlementOfAccruedLiability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for settlement of accrued liability.", "label": "Issuance of common stock - settlement of accrued liability (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForSettlementOfAccruedLiability", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "sharesItemType" }, "cenb_StockIssuedDuringPeriodSharesIssuedForSettlementOfLeaseTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents shares of stock issued for settlement of lease termination.", "label": "Issuance of common stock \u2013 lease termination settlement (in shares)", "terseLabel": "Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForSettlementOfLeaseTermination", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_StockIssuedDuringPeriodSharesSettlementOfAccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period for the settlement of accrued interest.", "label": "Issuance of common stock \u2013 settlement of accrued interest (in shares)", "terseLabel": "Stock Issued During Period, Shares, Settlement of Accrued Interest (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSettlementOfAccruedInterest", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "sharesItemType" }, "cenb_StockIssuedDuringPeriodValueIssuedForSettlementOfAccruedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued for settlement of accrued liability.", "label": "Issuance of common stock - settlement of accrued liability" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForSettlementOfAccruedLiability", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_StockIssuedDuringPeriodValueIssuedForSettlementOfLeaseTermination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents Value of stock issued for settlement of lease termination.", "label": "Issuance of common stock \u2013 lease termination settlement", "terseLabel": "Stock Issued During Period, Value, Issued for Settlement of Lease Termination" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForSettlementOfLeaseTermination", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "cenb_StockIssuedDuringPeriodValueSettlementOfAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period for the settlement of accrued interest.", "label": "Issuance of common stock \u2013 settlement of accrued interest" } } }, "localname": "StockIssuedDuringPeriodValueSettlementOfAccruedInterest", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_StockIssuedForSettlementOfAccruedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities for the settlement of accrued liability.", "label": "cenb_StockIssuedForSettlementOfAccruedLiability", "terseLabel": "Issuance of common stock - settlement of accrued liability" } } }, "localname": "StockIssuedForSettlementOfAccruedLiability", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_StockIssuedForSettlementOfInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities for the settlement of interest.", "label": "cenb_StockIssuedForSettlementOfInterest", "terseLabel": "Issuance of common stock - settlement of interest" } } }, "localname": "StockIssuedForSettlementOfInterest", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "cenb_TaxCreditsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for tax credits.", "label": "Tax Credits, Policy [Policy Text Block]" } } }, "localname": "TaxCreditsPolicyPolicyTextBlock", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "cenb_TeslaDigitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Tesla Digital.", "label": "Tesla Digital [Member]" } } }, "localname": "TeslaDigitalMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "cenb_TeslaDigitalTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Tesla Digital Transaction.", "label": "Tesla Digital Transaction [Member]" } } }, "localname": "TeslaDigitalTransactionMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "cenb_The2021EquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2021 equity compensation plan.", "label": "The 2021 Equity Compensation Plan [Member]" } } }, "localname": "The2021EquityCompensationPlanMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_UsamakhSaadikhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the Usamakh Saadikh, a member of the reporting entity's Board of Directors.", "label": "Usamakh Saadikh [Member]" } } }, "localname": "UsamakhSaadikhMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "domainItemType" }, "cenb_VestedImmediatelyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares vested immediately.", "label": "Vested Immediately [Member]" } } }, "localname": "VestedImmediatelyMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "cenb_XNPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to XN Pharma.", "label": "XN Pharma [Member]" } } }, "localname": "XNPharmaMember", "nsuri": "http://www.cenbiotechinc.com/20210930", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "cenb_statement-statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details)" } } }, "localname": "statement-statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-10-convertible-notes-payable-related-parties-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Convertible Notes Payable - Related Parties" } } }, "localname": "statement-statement-note-10-convertible-notes-payable-related-parties-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-13-leases-future-minimum-operating-lease-payments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Leases - Future Minimum Operating Lease Payments (Details)" } } }, "localname": "statement-statement-note-13-leases-future-minimum-operating-lease-payments-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-13-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Leases" } } }, "localname": "statement-statement-note-13-leases-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-14-income-taxes-deferred-tax-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Income Taxes - Deferred Tax Assets (Details)" } } }, "localname": "statement-statement-note-14-income-taxes-deferred-tax-assets-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Income Taxes - Reconciliation of Effective Tax Rate (Details)" } } }, "localname": "statement-statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-14-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Income Taxes" } } }, "localname": "statement-statement-note-14-income-taxes-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-17-stock-based-compensation-restricted-stock-award-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17 - Stock Based Compensation - Restricted Stock Award Activity (Details)" } } }, "localname": "statement-statement-note-17-stock-based-compensation-restricted-stock-award-activity-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-17-stock-based-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17 - Stock Based Compensation" } } }, "localname": "statement-statement-note-17-stock-based-compensation-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-18-net-loss-per-share-antidilutive-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 18 - Net Loss Per Share - Antidilutive Securities (Details)" } } }, "localname": "statement-statement-note-18-net-loss-per-share-antidilutive-securities-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-18-net-loss-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 18 - Net Loss Per Share" } } }, "localname": "statement-statement-note-18-net-loss-per-share-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 20 - Fair Value Disclosures - Fair Value of Financial Instruments (Details)" } } }, "localname": "statement-statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-20-fair-value-disclosures-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 20 - Fair Value Disclosures" } } }, "localname": "statement-statement-note-20-fair-value-disclosures-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-21-segment-information-segment-assets-to-total-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 21 - Segment Information - Segment Assets to Total Assets (Details)" } } }, "localname": "statement-statement-note-21-segment-information-segment-assets-to-total-assets-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-21-segment-information-segment-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 21 - Segment Information - Segment Information (Details)" } } }, "localname": "statement-statement-note-21-segment-information-segment-information-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-21-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 21 - Segment Information" } } }, "localname": "statement-statement-note-21-segment-information-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Acquisition of Clear Com Media, Inc - Estimate of Assets Acquired and Liabilities Assumed (Details)" } } }, "localname": "statement-statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Acquisition of Clear Com Media, Inc - Proforma Results of Operations (Details)" } } }, "localname": "statement-statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-3-acquisition-of-clear-com-media-inc-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Acquisition of Clear Com Media, Inc" } } }, "localname": "statement-statement-note-3-acquisition-of-clear-com-media-inc-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details)" } } }, "localname": "statement-statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-4-property-plant-and-improvements-net-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Property, Plant and Improvements, Net" } } }, "localname": "statement-statement-note-4-property-plant-and-improvements-net-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-6-intangible-assets-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets - Intangible Assets (Details)" } } }, "localname": "statement-statement-note-6-intangible-assets-intangible-assets-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-6-intangible-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets" } } }, "localname": "statement-statement-note-6-intangible-assets-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-7-loans-payable-loans-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Loans Payable - Loans Payable (Details)" } } }, "localname": "statement-statement-note-7-loans-payable-loans-payable-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-7-loans-payable-loans-payable-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-7-loans-payable-loans-payable-details-parentheticals", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-7-loans-payable-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Loans Payable" } } }, "localname": "statement-statement-note-7-loans-payable-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details)" } } }, "localname": "statement-statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-8-loans-payable-related-party-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Loans Payable- Related Party" } } }, "localname": "statement-statement-note-8-loans-payable-related-party-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-9-convertible-notes-convertible-notes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Convertible Notes - Convertible Notes (Details)" } } }, "localname": "statement-statement-note-9-convertible-notes-convertible-notes-details", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-9-convertible-notes-convertible-notes-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-note-9-convertible-notes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Convertible Notes" } } }, "localname": "statement-statement-note-9-convertible-notes-tables", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "cenb_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.cenbiotechinc.com/20210930", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r51", "r53", "r103", "r104", "r240", "r263" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r173", "r292", "r293", "r497" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r239", "r262", "r306", "r309", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r496", "r498", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r239", "r262", "r306", "r309", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r496", "r498", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r173", "r292", "r293", "r497" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r239", "r262", "r295", "r306", "r309", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r496", "r498", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r239", "r262", "r295", "r306", "r309", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r496", "r498", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r52", "r53", "r103", "r104", "r240", "r263" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r115", "r307" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r115", "r119", "r307" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r115", "r119", "r219", "r307", "r438" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r175", "r428" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "domainItemType" }, "srt_VicePresidentMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "label": "Vice President [Member]" } } }, "localname": "VicePresidentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35", "r435" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r35", "r102", "r427", "r429" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable \u2013 related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r21", "r176", "r177" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "auth_ref": [ "r476", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.", "label": "us-gaap_AccruedSalariesCurrentAndNoncurrent", "terseLabel": "Accrued Salaries" } } }, "localname": "AccruedSalariesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r206" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r55", "r56", "r57", "r486", "r503", "r504" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r54", "r57", "r64", "r65", "r66", "r107", "r108", "r109", "r375", "r499", "r500", "r519" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r329", "r435" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r107", "r108", "r109", "r326", "r327", "r328", "r379" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r85", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "us-gaap_AdjustmentForAmortization", "verboseLabel": "Amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r275", "r281", "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Beneficial conversion feature on convertible notes issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "auth_ref": [ "r275", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "terseLabel": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r311", "r323", "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r73", "r85", "r252", "r406" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r85", "r192", "r199" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r152", "r159", "r166", "r186", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r371", "r376", "r392", "r433", "r435", "r470", "r483" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r50", "r100", "r186", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r371", "r376", "r392", "r433", "r435" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r312", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r305", "r308" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r305", "r308", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r357", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "terseLabel": "Net income (loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r357", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "us-gaap_BusinessAcquisitionsProFormaRevenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities": { "auth_ref": [ "r361", "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities", "negatedTerseLabel": "Current financial liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "terseLabel": "Identifiable intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r361", "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "negatedTerseLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r361", "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r362" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r74" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash acquired upon acquisition of Clear Com Media, Inc." } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r30", "r87" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r81", "r87", "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r397" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r216", "r217", "r218", "r220", "r508" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r107", "r108", "r379" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, No Par Value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "us-gaap_CommonStockParOrStatedValuePerShare", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".", "label": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorizedUnlimited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" ], "xbrltype": "authorizedUnlimitedItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19", "r435" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; unlimited authorized shares; 47,786,013 and 27,557,363 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. No par value." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r59", "r61", "r62", "r68", "r478", "r494" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "terseLabel": "Net income (loss)", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r193", "r197", "r366" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r133", "r134", "r173", "r390", "r391", "r507" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r133", "r134", "r173", "r390", "r391", "r505", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r133", "r134", "r173", "r390", "r391", "r505", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r133", "r134", "r173", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r133", "r134", "r173", "r390", "r391", "r507" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r94", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "auth_ref": [ "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.", "label": "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "terseLabel": "Contingent Consideration Classified as Equity, Fair Value Disclosure" } } }, "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "us-gaap_ConvertibleDebtFairValueDisclosures", "verboseLabel": "Convertible notes payable" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r235", "r236", "r237", "r239", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r45" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes, less current portion" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r132", "r173" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r90", "r92" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r90", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionConvertedInstrumentAmount1", "terseLabel": "Issuance of common stock \u2013 upon conversion of convertible notes" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r90", "r92" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r90", "r92" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r90", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Instrument, Debt Default, Amount", "terseLabel": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r99", "r105", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r256", "r257", "r258", "r259", "r408", "r471", "r472", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r253", "r472", "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "us-gaap_DebtInstrumentCarryingAmount", "verboseLabel": "Long-term Debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature", "terseLabel": "Debt Instrument, Convertible, Beneficial Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r44", "r238", "r276", "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "Conversion Rights", "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r236", "r256", "r257", "r407", "r408", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Original Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42", "r237" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest Rate", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r43", "r239", "r383" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Maturity Date, end" } } }, "localname": "DebtInstrumentMaturityDateRangeEnd1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeStart1": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Maturity Date, start" } } }, "localname": "DebtInstrumentMaturityDateRangeStart1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45", "r99", "r105", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r256", "r257", "r258", "r259", "r408" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r243", "r406", "r409" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Less unamortized debt discount", "verboseLabel": "Less unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r339" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r343", "r344" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred tax asset - net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r338" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Deferred tax asset valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r85", "r204" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation, Total", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share", "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes" ], "xbrltype": "stringItemType" }, "us-gaap_DueFromAffiliateNoncurrent": { "auth_ref": [ "r11", "r426", "r428", "r432", "r469", "r482", "r506" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due after 1 year (or 1 business cycle).", "label": "Advances to CEN Biotech Ukraine LLC - related party" } } }, "localname": "DueFromAffiliateNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r102", "r225", "r227", "r228", "r232", "r233", "r234", "r426", "r474", "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "us-gaap_DueFromRelatedParties", "terseLabel": "Due from Related Parties, Total" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r102", "r225", "r227", "r228", "r232", "r233", "r234", "r426", "r475", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent", "terseLabel": "Due to Related Parties, Total" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r123", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r397" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r334" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r334", "r350" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r64", "r65", "r66", "r107", "r108", "r109", "r111", "r116", "r118", "r127", "r187", "r275", "r281", "r326", "r327", "r328", "r347", "r348", "r379", "r398", "r399", "r400", "r401", "r402", "r403", "r499", "r500", "r501", "r519" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r245", "r256", "r257", "r387" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r381", "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r245", "r256", "r257", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r382", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r245", "r256", "r257", "r381", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r245", "r296", "r297", "r302", "r304", "r382", "r440" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r245", "r256", "r257", "r296", "r297", "r302", "r304", "r382", "r441" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r245", "r256", "r257", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r382", "r442" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r245", "r256", "r257", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r198" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Less: Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r193", "r195", "r198", "r201", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r198", "r455" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Finite-lived intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r193", "r197" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r198", "r454" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "us-gaap_FinitelivedIntangibleAssetsAcquired1", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r393", "r394", "r395", "r396" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign exchange (loss) gain" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r86", "r395", "r396" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossUnrealized", "negatedLabel": "Foreign exchange loss (gain)" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r85", "r203", "r209" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "us-gaap_GainLossOnDispositionOfAssets", "negatedLabel": "Loss on disposal of property and equipment", "terseLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r411" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "us-gaap_GainLossOnTerminationOfLease", "negatedLabel": "Loss on operating lease right-of-use asset - lease termination settlement", "terseLabel": "Gain (Loss) on Termination of Lease" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r188", "r189", "r435", "r468" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r85", "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "us-gaap_ImpairmentOfRealEstate", "terseLabel": "Impairment of Real Estate" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r210", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r101", "r335", "r336", "r341", "r349", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r63", "r332", "r333", "r336", "r337", "r340", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties", "verboseLabel": "Accounts payable \u2013 related parties" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsPayableTrade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable", "negatedLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities which provided (used) cash, net of amounts acquired in 2021 business acquisition" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherReceivables", "negatedLabel": "Other receivable" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r95", "r197", "r450", "r451", "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r191", "r196" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r73", "r250", "r255", "r258", "r259" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "us-gaap_InterestExpenseDebt", "negatedLabel": "Interest expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "us-gaap_InterestExpenseRelatedParty", "negatedLabel": "Interest expense \u2013 related parties", "terseLabel": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r80", "r82", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r40" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_InterestPayableCurrent", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r85" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock-based compensation \u2013 non-employees" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Consulting fees and subcontractors" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r420" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r100", "r160", "r186", "r222", "r223", "r224", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r372", "r376", "r377", "r392", "r433", "r434" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r100", "r186", "r392", "r435", "r473", "r488" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r100", "r186", "r222", "r223", "r224", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r372", "r376", "r377", "r392", "r433", "r434", "r435" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r36", "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r36", "r99" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "us-gaap_LoansPayableFairValueDisclosure", "verboseLabel": "Loans payable" } } }, "localname": "LoansPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableFairValueDisclosure": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.", "label": "us-gaap_LoansReceivableFairValueDisclosure", "verboseLabel": "Other receivables" } } }, "localname": "LoansReceivableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r244", "r254", "r256", "r257", "r472", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-term Debt, Total", "verboseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebtCurrent", "verboseLabel": "Less current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebtNoncurrent", "verboseLabel": "Convertible notes payable, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r45" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "CEBA loan payable", "terseLabel": "Loans Payable, Noncurrent, Total" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r221" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r83", "r86" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r58", "r60", "r66", "r67", "r86", "r100", "r110", "r112", "r113", "r114", "r115", "r117", "r118", "r121", "r152", "r158", "r162", "r165", "r168", "r186", "r222", "r223", "r224", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r380", "r392", "r477", "r493" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash transactions - investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNameDomain": { "auth_ref": [ "r90", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "The name of the sale of an asset or business acquired through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Acquisition, Name [Domain]" } } }, "localname": "NoncashOrPartNoncashAcquisitionNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition of Clear Com Media, Inc.:" } } }, "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "auth_ref": [ "r90", "r91", "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "terseLabel": "Fair value of assets acquired" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "auth_ref": [ "r90", "r91", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "terseLabel": "Liabilities assumed" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis": { "auth_ref": [ "r90", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "This table is organized by a unique description of the noncash or part noncash acquisition.", "label": "Noncash or Part Noncash Acquisitions by Unique Description [Axis]" } } }, "localname": "NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r90", "r91", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Issuance of note payable for services" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r34", "r102", "r427" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Loans payable \u2013 related parties" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r102", "r426", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent", "terseLabel": "Notes Payable, Related Parties" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableRelatedParties": { "auth_ref": [ "r102", "r426", "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.", "label": "us-gaap_NotesReceivableRelatedParties", "terseLabel": "Notes Receivable, Related Parties" } } }, "localname": "NotesReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableRelatedPartiesCurrent": { "auth_ref": [ "r49", "r102", "r426" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).", "label": "Loan receivable from Emergence Global Enterprises Inc. - related party", "terseLabel": "Notes Receivable, Related Parties, Current" } } }, "localname": "NotesReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableRelatedPartiesNoncurrent": { "auth_ref": [ "r11", "r20", "r102", "r426" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).", "label": "Note receivable - CEN Biotech Ukraine LLC - related party" } } }, "localname": "NotesReceivableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r152", "r158", "r162", "r165", "r168" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "verboseLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r414" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r410" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Loss on operating lease right-of-use asset - lease abandonment", "terseLabel": "Operating Lease, Impairment Loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liability", "terseLabel": "Operating Lease, Liability, Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r413" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r413" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r412" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r419", "r421" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r418", "r421" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r106", "r120", "r138", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other assets" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r369", "r370", "r374" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other comprehensive loss - Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r85" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Shares issued for interest" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of equipment", "verboseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r77" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "us-gaap_PaymentsToDevelopSoftware", "negatedLabel": "Capitalized software development" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r76", "r425" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "us-gaap_PaymentsToFundLongtermLoansToRelatedParties", "negatedLabel": "Advances to CEN Biotech Ukraine LLC" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r312", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member] [Default]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r28", "r29" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r78" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Issuance of convertible notes", "terseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r78" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Issuance of convertible notes \u2013 related parties" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r75" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from sale of equipment", "terseLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r33", "r207" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r212", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r32", "r205" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r207", "r435", "r479", "r489" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r31", "r207", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r205" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r159", "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r303", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r425", "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r303", "r425", "r426", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r303", "r425", "r429", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r423", "r424", "r426", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "us-gaap_RepaymentsOfRelatedPartyDebt", "negatedLabel": "Repayment of loans payable - related parties" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r281", "r329", "r435", "r487", "r502", "r504" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit), Ending Balance" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r107", "r108", "r109", "r111", "r116", "r118", "r187", "r326", "r327", "r328", "r347", "r348", "r379", "r499", "r501" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r143", "r144", "r157", "r163", "r164", "r170", "r171", "r173", "r291", "r292", "r453" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r294" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r133", "r173" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r45", "r105", "r256", "r258", "r276", "r278", "r279", "r280", "r406", "r407", "r409", "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r193", "r197" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r152", "r155", "r161", "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r139", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r157", "r158", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r173", "r214", "r215", "r495" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r139", "r141", "r142", "r152", "r156", "r162", "r166", "r167", "r168", "r169", "r170", "r172", "r173", "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r84" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock based compensation", "verboseLabel": "Stock-based compensation \u2013 employees" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited, number of share (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted, number of share (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Non-vested, number of share (in shares)", "periodStartLabel": "Non-vested, number of share (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Non-vested, weighted average grant date fair value (in dollars per share)", "periodStartLabel": "Non-vested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-vested, weighted average remaining contractual term (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, number of share (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r310", "r314" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r14", "r435", "r471", "r484" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "us-gaap_ShortTermBorrowings", "terseLabel": "Loan payable" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-term Debt [Text Block]" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r139", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r157", "r158", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r173", "r190", "r211", "r214", "r215", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r48", "r64", "r65", "r66", "r107", "r108", "r109", "r111", "r116", "r118", "r127", "r187", "r275", "r281", "r326", "r327", "r328", "r347", "r348", "r379", "r398", "r399", "r400", "r401", "r402", "r403", "r499", "r500", "r501", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r107", "r108", "r109", "r127", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-", "http://www.cenbiotechinc.com/20210930/role/statement-note-12-governmental-assistance-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-future-minimum-operating-lease-payments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-deferred-tax-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-reconciliation-of-effective-tax-rate-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity", "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions", "http://www.cenbiotechinc.com/20210930/role/statement-note-16-related-party-transactions-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-restricted-stock-award-activity-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-antidilutive-securities-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-19-contingency", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans", "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-fair-value-of-financial-instruments-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-assets-to-total-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-segment-information-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-estimate-of-assets-acquired-and-liabilities-assumed-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-proforma-results-of-operations-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-", "http://www.cenbiotechinc.com/20210930/role/statement-note-5-advances-to-cen-biotech-ukraine-and-loan-receivable-from-emergence-global-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-loans-payable-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r90", "r91", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "us-gaap_StockIssued1", "terseLabel": "Issuance of common stock - acquisition of Clear Com Media, Inc." } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r18", "r19", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Issuance of common stock - acquisition of Clear Com Media, Inc. (in shares)", "terseLabel": "Stock Issued During Period, Shares, Acquisitions (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r247", "r275", "r276", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Issuance of common stock \u2013 upon conversion of convertible notes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock - consulting (in shares)", "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r275", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock \u2013 interest shares (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets", "terseLabel": "Stock Issued During Period, Shares, Purchase of Assets (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r48", "r275", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Issuance of common stock - acquisition of Clear Com Media, Inc.", "terseLabel": "Stock Issued During Period, Value, Acquisitions" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r48", "r275", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of common stock \u2013 upon conversion of convertible notes", "terseLabel": "Issuance of common stock \u2013 upon conversion of convertible notes", "verboseLabel": "Issuance of common stock \u2013 upon conversion of convertible notes \u2013 related parties" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock - consulting", "terseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r275", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock \u2013 interest shares", "terseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r25", "r26", "r100", "r183", "r186", "r392", "r435" ], "calculation": { "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-", "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-balance-sheets-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r98", "r261", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-15-shareholders-deficit-stock-activity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r404", "r437" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r404", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r404", "r437" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.cenbiotechinc.com/20210930/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties", "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events", "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-details-textual", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-22-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-2-going-concern-uncertainty-management-plans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flows disclosures" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-10-convertible-notes-payable-related-parties-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-13-leases-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-18-net-loss-per-share-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-20-fair-value-disclosures-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-21-segment-information-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-3-acquisition-of-clear-com-media-inc-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-4-property-plant-and-improvements-net-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-7-loans-payable-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-8-loans-payable-related-party-tables", "http://www.cenbiotechinc.com/20210930/role/statement-note-9-convertible-notes-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r178", "r179", "r180", "r181", "r182", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-6-intangible-assets-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-", "http://www.cenbiotechinc.com/20210930/role/statement-note-11-ceba-loan-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r128", "r129", "r130", "r131", "r135", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-14-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation", "http://www.cenbiotechinc.com/20210930/role/statement-note-17-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cenbiotechinc.com/20210930/role/statement-condensed-consolidated-statements-of-operations-and-other-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r422": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3)(a)(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r514": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r515": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r516": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r517": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r518": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" }